



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

		1 10/00/21 (03-04)
Application Number	10/630,223	
Filing Date	July 30, 2003	
First Named Inventor	Michon, Francis	-
Art Unit	1615	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	20695C-001410US	

			ENCLO	SURES (Ch	eck all that apply	y)		
Ar E	extension of Time express Abandonn formation Disclos	leclaration(s) Request nent Request	Drav Lice Petii Prov Cha Terr Req	wing(s) nsing-related Pap	ers a n vocation dence Address	Af Ap Ap Of Ap	opeal Cor Appeals opeal Cor ppeal Not oprietary atus Lette ther Encle elow):	ance Communication to TC mmunication to Board and Interferences mmunication to TC ice, Brief, Reply Brief) Information er osure(s) (please identify A26-A47; Return Postcard
				Landscape Tat				dditional for the Donney
	ertified Copy of P locument(s)	riority	Remarks	Account 20-		zea to cnarç	ge any a	dditional fees to Deposit
		arts/ Incomplete issing Parts FR 1.52 or 1.53						
-		SIGNA	TURE OF A	APPLICANT,	ATTORNEY, O	OR AGEN	Т	
Firm Name	Town	send and Towns	send and Cr	ew LLP				
Signature		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	$\overline{\Lambda}$	1/4				
Printed na	ame Jean	M. Lockver, Ph.	D. >					
Date	7-	15-05		/	Reg. No.	44,879		
CERTIFICATE OF TRANSMISSION/MAILING								
		orrespondence is be commissioner for Pa						age as first class mail in an elow.
Signature	e	a	he)				
Typed or	printed name	Anna C. Kund	el				Date	07-15-05

I kereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 20695C-001410US Client Reference No.: NV-1936

Commissioner for Patents

Box 1450

Alexandria, VA 22313-1450

on July 15, 2005

TOWNSEND and TOWNSEND and CREW LLP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Francis MICHON, et al.

Application No.: 10/630,223

Filed: July 30, 2003

For: CHIMERIC MULTIVALENT POLYSACCHARIDE CONJUGATE

VACCINES

Examiner: Not Yet Assigned

Art Unit: 1615

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Francis MICHON, et al. Application No.: 10/630,223

Page 2

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Jean M. Lockyer, Ph.I

Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

JML:ack 60531904 v1



stitute for form 1449A&B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	,,,,,,		 	,	•
Sheet	7	1 ,	\f	3	_

Complete if Known						
Application Number	10/630,223					
Filing Date	July 30, 2003					
First Named Inventor	Michon, Francis					
Art Unit	1615					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	20695C-001410US					

			U.S. PATENT DO	CUMENTS+	
Examiner Initials*	Cite No.1	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-4,356,170	10-26-1982	Jennings et al.	<u>g</u>
·	A2	US-4,619,828	10-28-1986	Gordon	
	A3	US-4,644,059	02-17-1987	Gordon	
	A4	US-4,673,574	06-16-1987	Anderson	
	A5	US-4,711,779	12-08-1987	Porro et al.	
	A6	US-4,727,136	02-23-1988	Jennings et al.	
	A7	US-4,761,283	08-02-1988	Anderson	
	A8	US-4,789,735	12-06-1988	Frank et al.	
	A9	US-5,425,946	06-20-1995	Tai, et al.	
	A10	US-5,439,808	08-08-1995	Blake et al.	
	A11	US-5,597,572	01-28-1997	Huergo et al.	
	A12	US-5,614,382	03-25-1997	Metcalf	
	A13	US-5,651,971	07-29-1997	Lees	· · · · · · · · · · · · · · · · · · ·
	A14	US-5,705,580	01-06-1998	Giberti	
	A15	US-5,811,102	09-22-1998	Jennings et al.	
	A16	US-5,820,860	10-31-1998	Michel et al.	
	A17	US-5,843,444	12-01-1988	Michel et al.	
	A18	US-5,843,461	12-01-1998	Jennings et al.	
	A19	US-5,847,081	12-08-1998	Michel et al.	
	A20	US-5,858,362	01-12-1999	Michel et al.	,
	A21	US-5,908,629	06-01-1999	Michel et al.	
	A22	US-5,968,521	10-19-1999	Michel et al.	
	A23	US-5,993,825	11-30-1999	Jennings et al.	
	A24	US-6,013,267	01-11-2000	Blake et al.	
	A25	US-6,248,570	06-19-2001	Michon et al.	

						T	Dagge Columns Lines	$\overline{}$
Examiner Initials*	Cite No. ¹	Country Code ³	reign Patent Docu	Mind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	A26	EP	245,045	A2	11-11-1987	Praxis Biologics, Inc.		
	A27	EP	206,852	A1	12-30-1986	Universite Catholique de Louvain		⋈
	A28	EP	0 467 714	A1	01-22-1992	Merck & Co., Inc.		
	A29	EP	504,202	B1	05-03-1995	National Research Council of Canada		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known			
INITAL		DIO		Application Number	10/630,223		
			CLOSURE	Filing Date	July 30, 2003		
STAT	EMENT B	ΥA	PPLICANT	First Named Inventor	Michon, Francis		
				Art Unit	1615		
(t	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned			
Sheet	2	of	3	Attorney Docket Number	20695C-001410US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A30	ALLEN, J., et al., "Pursuit of Optimal Carbohydrate-Based Anticancer Vaccines: Preparation of a Multiantigenic Unimolecular Glycopeptide Containing the Tn, MBr1, and Lewis Antigens," <u>J. Am. Chem. Soc.</u> , 2001, Vol. 123, pp. 1890-1897.	
	A31	BESSLER, W.G. et al., "Specific Antibodies Elicited by Antigen Covalently Linked to a Synthetic Adjuvant," linked to a Synthetic Adjuvant, " linked to a Synthetic Adjuvant, " linked to-asynthetic-adjuvant, " <a <u="" a="" and="" antigens:="" bacterial="" carbohydrate="" consideration="" design="" factors,"="" glyconjugates="" href="mailto:linked-to-asynthetic-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adjuvant-adj</td><td></td></tr><tr><td></td><td>A32</td><td>DICK, et al., " of="" preparation="" survey="">Conjugate Vaccines, Eds., Cruse, et al., Karger, Basel, 1989, pp. 48-114.	
	A33	FEAVERS, I.M., et al., "Molecular Analysis of the Serotyping Antigens of Neisseria meningitides," Infect. Immun. , 1992, 60:3620-3629.	
	A34	FRASCH, C. et al., "Serotype Antigens of <i>Neisseria meningitidis</i> and a Proposed Scheme for Designation of Serotypes," Rev. Infect. Dis., 1985, 7:504-510.	
	A35	GHOSE, A., et al., "Induction of Polyclonal and Monoclonal Antibody Responses to Cholera Toxin by the Synthetic Peptide Approach," Molec. Immunol., 1988, 25:223-230.	
	A36	JACOB, C., et al., "Priming immune response to cholera toxin induced by synthetic peptides," <u>Eur. J. Immunol.</u> , 1986, 16:1057-1062.	
_	A37	KASPER, D., et al., "Bacterial Capsule - Old Dogmas and New Tricks," <u>J. of Infect. Dis.</u> , 1986, 153:407-415.	
	A38	KLIPSTEIN, F., et al., "Development of a Vaccine of Cross-Linked Heat-Stable and Heat-Labile Enterotoxins That Protects Against <i>Escherichia coli</i> Producing Either Enterotoxin," <u>Infect. Immun.</u> , 1982, 37:550-557	
	A39	MARBURG, S., et al., "Bimolecular Chemistry of Macromolecules: Synthesis of Bacterial Polysaccharide Conjugates with <i>Neisseria meningitidis</i> Membrane Protein," <u>J. Am. Chem. Soc.</u> , 1986, 108, 5282-5287.	
	A40	MURAKANI, K., et al., "Cloning and Characterization of the Structural Gene for the Class 2 Protein of Neisseria meningitidis," Infect. Immun., 1989, 57:2318-2323.	
	A41	PARKER, J. M., et al., "A General Method to Prepare Synthetic Peptide Conjugates," <u>Modern Approaches to Vaccines</u> , Chanock, et al., eds., 1983, pp. 133-138, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.	
	A42	POSNETT, D., et al., "A Novel Method for Producing Anti-Peptide Antibodies," <u>J. Biol. Chem.</u> , 1988, 263:1719-1725.	
	A43	SCHNEERSON, R., et al., "Preparation, Characterization, and Immunogenicity of Haemophilus Influenzae Type _b Polysaccharide-Protein Conjugates," J. Exp. Med., 1980, 1952:361-476.	
	A44	UCHIDA, T., et al., "Mutation in the Structural Gene for Diphtheria Toxin carried by Temperate Phage β," Nature New Biology, 1971, 233:8-11.	

Examiner Date					
Litatililei		Evaminer	n	ate	
	Signature	LAGITIIITEI		ale	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449A&B/	PTO			Complete if Known
11150		DIC.	OL COURT	Application Number	10/630,223
			CLOSURE	Filing Date	July 30, 2003
STAT	EMENT B	Y A	PPLICANT	First Named Inventor	Michon, Francis
				Art Unit	1615
(4	ise as many sh	eets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	20695C-001410US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A45	WILKINSON, H., et al., "Serological Relationships of Type I Antigens of Group B Streptococci," <u>J. Bacteriol.</u> , 1969, 97:629-634.	
	A46	WILKINSON, H.W., et al., "Type-Specific Antigens of Group B Type Ic Streptococci," Infec. and Immun., 1971, 4:596-604.	
	A47	ZURAWSKI, V., et al., "Antibodies of Restricted Heterogeneity Directed Against the Cardiac Glycoside Digoxin," J. Immunol., 1978, 121:122-139.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.